Biomarkers and cardiovascular risk in disease models of non-alcoholic fatty liver disease

Completed

• Conditions: fatty liver; nonalcoholic fatty liver disease (NAFLD); 10019654; 10021605; 10003216

• Registration Number: NL-OMON48654
• Lead Sponsor: Medisch Universitair Ziekenhuis Maastricht

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 15 April 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 85

Inclusion Criteria

Healthy individuals:
- age ><= 18 years, NAFLD disease models (n<=15 per group):
- diagnosis of glycogen storage disease 1a (GSD1a), familial partial
lipodystrophy (FPL), maturity-onset diabetes of the young type 2 (MODY2) or
abetalipoproteniemia/familial hypobetalipoproteinemia
- age ><= 18 years

Exclusion Criteria

- Contraindications for MRI (i.e. claustrophobia, heart pacemaker or other
electronic devices implanted in the body, history of collapse or seizure, or
pregnancies < 12 weeks)
- Inability to give inform consent

Study & Design

• Study Type: Observational invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>a set of candidate biomarkers of DNL measured in plasma</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>Secondary outcome: endothelial function (reactive hyperaemia peripheral<br /><br>applanation tonometry, laser doppler flowmetry and plasma biomarkers)<br /><br>Other parameters: hepatic fat accumulation (magnetic resonance spectroscopy)<br /><br>and fat distribution (MRI)</p><br>